	1
1	IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO EASTERN DIVISION
۷	EASIERN DIVISION
3	IN RE: NATIONAL : MDL No. 2804 PRESCRIPTION OPIATE :
4	LITIGATION : Case No. 17-md-2804 :
5	APPLIES TO ALL CASES : Hon. Dan A. Polster :
6	: :
7	
8	HIGHLY CONFIDENTIAL
9	SUBJECT TO FURTHER CONFIDENTIALITY REVIEW
10	
11	
12	JANUARY 8, 2019
13	
14	VIDEOTAPED DEPOSITION OF GREGORY CARLSON,
15	taken pursuant to notice, was held at Marcus &
16	Shapira, One Oxford Center, 35th Floor, Pittsburgh,
17	Pennsylvania 15219, by and before Ann Medis,
18	Registered Professional Reporter and Notary Public in
19	and for the Commonwealth of Pennsylvania, on Tuesday,
20	January 8, 2019, commencing at 9:06 a.m.
21	
22	GOLKOW LITIGATION SERVICES
23	877.370.3377 phone 917.591.5672 fax deps@golkow.com
24	
25	

```
2
 1
                       APPEARANCES
      On behalf of Plaintiffs
 2
 3
                WAGSTAFF & CARTMELL, LLP
                BY: TOM ROTTINGHAUS, ESQUIRE
                4740 Grand Avenue, Suite 300
 4
                Kansas City, Missouri 64112
                816.701.1100
 5
                trottinghaus@wcllp.com
 6
 7
      On behalf of Defendant AmerisourceBergen Drug
      Corporation
 8
                (By Phone/Livestream)
                REED SMITH LLP
 9
                BY: SHANA E. RUSSO, ESQUIRE
10
                136 Main Street, Suite 250
                Princeton Forrestal Village
                Princeton, New Jersey
11
                609.514.5959
                srusso@reedsmith.com
12
13
      On behalf of Defendant Cardinal Health, Inc.
14
                PIETRAGALLO GORDON ALFANO BOSICK &
                RASPANTI, LLP
15
                BY: JENNIFER BOURIAT, ESQUIRE
                One Oxford Centre, 38th Floor
                301 Grant Street
17
                Pittsburgh, Pennsylvania 15219
                412.263.2000
                jhb@pietragallo.com
18
19
      On behalf of Defendants Endo Pharmaceuticals, Endo
20
      Health Solutions and Par Pharmaceuticals
                (By Phone/Livestream)
21
                ARNOLD & PORTER KAYE SCHOLER LLP
                BY: ERICA I. GUTHRIE, ESQUIRE
22
                601 Massachusetts Avenue, NW
23
                Washington, DC 20001-37453
                202.942.5743
24
                erica.guthrie@arnoldporter.com
25
```

```
3
                 A P P E A R A N C E S (Continued)
 1
 2
      On behalf of Defendant HBC Service Company
 3
                MARCUS & SHAPIRA, LLP
                BY: JOSHUA KOBRIN, ESQUIRE
                     ROBERT M. BARNES, ESQUIRE
 4
                One Oxford Centre, 35th Floor
                Pittsburgh, Pennsylvania 15219
 5
                412.471.3490
                jkobrin@marcus-shapira.com
 6
                rbarnes@marcus-shapira.com
 7
      On behalf of Defendant McKesson Corporation
 8
 9
                COVINGTON & BURLING, LLP
                BY: AMBER CHARLES, ESQUIRE
10
                One CityCenter
                850 Tenth Street, NW
                Washington, DC 20001-4956
11
                202.662.5807
                acharles@cov.com
12
13
      On behalf of Defendant Walmart
14
                (By phone/Livestream)
                JONES DAY, LLP
15
                BY: CHRISTOPHER MARKHAM, ESQUIRE
16
                100 High Street
                21st Floor
17
                Boston, Massachusetts 02110-1781
                617.960.3939
                cmarkham@jonesday.com
18
19
      On behalf of Deponent
20
                DICKIE MCCAMEY & CHILCOTE, P.C.
                BY: JEFFREY J. WETZEL, ESQUIRE
21
                Two PPG Place, Suite 400
                Pittsburgh, Pennsylvania 15222
22
                412.392.5617
23
                jwetzel@dmclaw.com
24
      Also present
25
                Frank Stanek, legal videographer
```

			А
			4
1		* I N D E X *	
2	GREGORY CAR	PAGE	
3			246, 252 217, 251
4	11227 11 11 11 11 11	211, 231	
5		* INDEX OF HBC-CARLSON EXHIBITS *	
6	NO.	DESCRIPTION	PAGE
7		Greg Carlson LinkedIn profile	13
8	Exhibit 2	Giant Eagle Retail Operations - Pharmacy Operations org chart	45
9		as of November 13, 2014 HBC_MDL00002216	
10	Exhibit 3	CFR Part 1301.74 from DEA website P1.47 - P1.47.2	52
11	Exhibit 4	DEA Dear Registrant 6/12/12,	89
12		6/12/12, 12/27/07, 2/7/07, 9/27/06 letters	
13		ABDCMDL00269683 - 00269694	
14	Exhibit 5	Ohio State Board of Pharmacy Meeting Minutes November 2-4, 2009	101
15 16	Exhibit 6	Ohio State Board of Pharmacy Meeting Minutes December 5-7, 2011	101
17	Exhibit 7	Email chain, 1/30/12, from A.	107
18		Zelaski to G. Carlson, et al., subject: RE: HBC phone number HBC MDL00090001 - 00090004	
19	Exhibit 8	_	110
20	EXHIDIC 8	Meeting invitation for 5/24/13, from J. Millward to G. Carlson, et al., subject: CSMP Questionnair	
21		Complete Response HBC_MDL00144314 - 00144322	
22	Exhibit 9	Email, 8/22/13, from S. Voyten to	114
23		J. Millward, et al., subject: FW: CVS News Story	
24		HBC_MDL00154265 - 00154266	
25			

				5		
1	* INDEX OF HBC-CARLSON EXHIBITS (Continued) *					
2	NO. Exhibit 10	DESCRIPTION Email chain, 4/18/14, from M. Bianco	PAGE 116			
3		to G. Carson, subject: Re: 35 missing tote				
4		HBC_MDL00135668 - 00135670				
5	Exhibit 11	Email chain, 4/23/14, from TammySSD to B. Snider, subject: Re: Missing	118			
6		HBC Tote MCKMDL0059574 - 0059578				
7	Exhibit 12		121			
8		Shaheen to G. Carlson, subject: RE: Procedural inconsistency				
9		HBC_MDL00063991 - 00063992				
10	Exhibit 13	Roahrig to J. Millward, subject:	128			
11		FW: Daily HBC Suspicious Purchasing Report - 11/13/13				
12	Exhibit 14	HBC_MDL00094599 - 0094600 Email chain, 8/20/15, from G.	134			
14	EXIIIDIC 14	Carlson to J. Jenson, et al., subject: FW: Thrifty White Notes	134			
15		HBC_MDL00069566 - 00069571				
16	Exhibit 15	Email chain, 10/23/08, from S. Cook to G. Carlson, subject: Giant	153			
17		Eagle CSMP Thresholds MCKMDL00628660 - 00628673				
18	Exhibit 16	Email chain, 2/23/09, from S. Cook	157			
19		to D. Gustin, subject: RE: Giant Eagle CSMP Thresholds				
20		MCKMDL00628614 - 00628616				
21	Exhibit 17	Daily HBC Controls report, 10/31/13 HBC_MDL00002348	160			
22	Exhibit 18	Email chain, 7/30/13, from 1217	166			
23		Pharmacy Team Leader to G. Carlson, subject: RE: Oxycodone Threshold				
24		HBC_MDL000174163				
25						

```
6
           * INDEX OF HBC-CARLSON EXHIBITS (Continued) *
 1
 2
      NO.
                             DESCRIPTION
                                                         PAGE
      Exhibit 19 Email chain, 9/19/13, from G.
 3
                  Carlson to A. Lowther, subject: RE:
                                                          168
                  Controls at HBC
                  HBC MDL00135579 - 00135580
 4
      Exhibit 20 Email chain, 9/9/13, from G.
                                                         168
 5
                  Carlson to K. Remas, subject: RE:
                  Controls at HBC
 6
                  HBC MDL00135022 - 00135024
 7
      Exhibit 21 HBC Service Company's Responses to
                                                         175
                  Plaintiffs' (First) Set of Combined
 8
                  Discovery Requests
 9
      Exhibit 22 Email, 1/22/14, from J. Millward to
                                                         176
10
                  G. Carlson, et al., subject: FW:
                  Wholesale Distributor Questionnaire,
                  attaching Qualitest Wholesale
11
                  Distributor/Chain Distribution
                  Center Questionnaire
12
                  HBC MDL00135570 - 00135574
13
      Exhibit 23 Giant Eagle Pharmacy Fiscal Year
                                                         187
14
                  2015 AOP/Business Plan, 6/24/14
                  HBC MDL00034115 - 00034149
15
      Exhibit 24 Giant Eagle Inventory Control -
                                                         191
                  Suspicious Order Policies with
16
                  various effective dates
17
                  HBC MDL00078638 - 00078639
                  HBC MDL00004386 - 00004387
                  HBC MDL00045916 - 00078918
18
                  HBC MDL00051908
                  HBC MDL00043414
19
                  HBC MDL00010092 - 00010093
20
      Exhibit 25 2009-2014 Hydrocodone Dosage Unit
21
                                                         209
                  Distribution to Giant Eagle
                  Pharmacies in Cuyahoga County,
22
                  Summit County, and all of Ohio
23
                  P-HBC-0017
24
25
```

```
7
                       PROCEEDINGS
 1
 2
 3
                MR. ROTTINGHAUS: We are now on the
     record. My name is Frank Stanek. I'm the
 4
     videographer for Golkow Litigation Services.
     Today's date is January 8, 2019, and the time is
 6
     9:06 a.m.
 7
           This video deposition is being held in
 8
     Pittsburgh, Pennsylvania, In Re: National
 9
10
     Prescription Opiate Litigation, for the United
     States District Court, for the Northern District
11
12
     of Ohio, Eastern Division.
13
           The deponent is Greg Carlson.
           Will counsel please identify themselves.
14
15
                MR. ROTTINGHAUS: Tom Rottinghaus on
     behalf of plaintiff.
16
                MS. BOURIAT: Jennifer Bouriat on behalf
17
     of Cardinal.
18
                MS. CHARLES: Amber Charles on behalf of
19
2.0
     McKesson.
21
                MR. KOBRIN: Josh Kobrin, Marcus &
     Shapira, on behalf of HBC Service Company.
22
23
                MR. WETZEL: Jeffrey Wetzel for
24
     Mr. Carlson personally.
25
                MR. BARNES: Robert Barnes, Marcus &
```

```
8
      Shapira, for Mr. Carlson.
 1
                MR. ROTTINGHAUS: Then do we have
 2
 3
      anybody participating by telephone?
                MR. MARKHAM: Chris Markham on behalf of
 4
      Walmart.
 5
                MS. RUSSO: Shana Russo on behalf of
 6
 7
      Amerisource Bergen Drug Corporation, of Reed
      Smith.
 8
                MS. GUTHRIE: Erica Guthrie of Arnold &
 9
      Porter on behalf of the Endo and Par defendants.
10
                         GREGORY CARLSON,
11
12
            having been first duly sworn, was examined
13
                     and testified as follows:
14
                            EXAMINATION
      BY MR. ROTTINGHAUS:
15
           Q. Good morning, Mr. Carlson.
16
17
           A. Good morning.
                My name is Tom Rottinghaus. We met
18
      right before the deposition; correct?
19
2.0
           Α.
                Yes.
21
                Thank you for coming here today. You
22
      understand you are here to give a deposition in a
23
      case involving your involvement, I guess, at Giant
24
      Eagle and HBC warehouse between, as I understand
      it, 2007 and 2016?
25
```

9 1 Α. Yes. I'm going to be asking you a series of 2 Q. questions today about your involvement or your 3 capacity in those institutions. There are going 4 to be several documents we're going to talk about as well. I've taken the liberty of marking a few 6 7 documents that we will be talking about that I 8 think you have in front of you. You understand you've just taken an oath to 9 10 tell the truth? Α. 11 Yes. 12 And this is the same type of testimony 13 you would give as if you were in a courtroom; correct? 14 15 Α. Yes. It's my understanding you may not be 16 able to be present at the time of trial, so you 17 understand that this testimony you give today is 18 19 being videotaped and may be played for a jury at 2.0 the time of trial if you are not available to be there in person? 21 22 Α. Yes. It's going to be very important for me 23 24 to make sure that you and I understand each other today. If I ask you any questions that you don't 25

```
10
 1
      understand, I want you to please stop me, let me
      know you don't understand it, and I'll do my best
 2
      to rephrase that question. Okay?
 3
           Α.
                Okay.
 4
                Similarly, it won't be my intention to
      interrupt you before you finish an answer.
 6
 7
      However, if I do so unintentionally, please let me
 8
      know you have not finished your answer. We'll
      stop. We'll give you a chance to finish your
 9
10
      answer. Okay?
11
           Α.
                Okay.
12
                You're doing a great job of audiblizing
13
      you answers. One thing I may ask you to do at
14
      times is to give an audible answer because
15
      sometimes in conversations, we just nod our heads
      or say "uh-huh" or "huh-uhn," but I may need to
16
      ask you to give me a "yes" or "no" answer at
17
      times. Okay?
18
19
           Α.
                Okay.
20
           Q.
                I don't intend to be rude to you if I do
21
      that. It's just that we need to have a clear
      record. Okay?
22
23
           Α.
                Okay.
24
           Q.
                It's my understanding you at this time,
      point in time, no longer work for the Giant Eagle
25
```

11 HBC system; is that correct? 1 Α. 2 Correct. 3 Ο. However, you are here with counsel for HBC; is that correct? 4 Α. Correct. Now, I don't get to find out and I'm not 6 7 asking you what you have talked with counsel about 8 in preparation for this deposition, but I would like to know or get a general understanding of 9 10 what you have reviewed irrespective of correspondence from your counsel in preparation 11 12 for the deposition. 13 For instance, I'm wondering if you've looked at prior emails from your time at the company or 14 any other documents. 15 Α. I have. 16 Let's kind of break it down. First of 17 all, you've had some time to prepare to give your 18 testimony today; correct? 19 2.0 Α. Yes. 21 And I'm assuming that in preparation for 22 your testimony, you did want to look at some 23 documents that went back to the timeframe in which 24 you were involved at HBC? 25 Α. Yes.

12 1 Ο. And you had a chance to do that? Α. 2 Yes. 3 Ο. I suspect that some of those documents we will be talking about today. It won't be my 4 intention to put anything in front of you that's not, to the best of my understanding, a genuine 6 7 document that was given to us by the company. But 8 if at any point in time you don't understand what a document is or you need to take a few more 9 minutes to look at it, you let us and we'll give 10 you a chance to do that. Okay? 11 12 Α. Okay. 13 Can you give us an approximation as to how much time in terms of hours you have spent 14 15 getting ready for this testimony today? I would say roughly eight hours. 16 I don't get to hear what you talked 17 about. But you obviously had a chance to talk to 18 your attorney and meet with your attorney? 19 2.0 Α. Uh-huh. 21 Ο. "Yes"?

> Yes. I met with the attorneys. Α.

22

23

24

25

And have you also had the opportunity or taken time to try to speak to anyone who is still at Giant Eagle with respect to any questions or

13 1 thoughts you may have had as you got ready for the deposition? 2 3 Α. I've not spoken with anybody at Giant Eagle about the deposition. 4 And I know sometimes they're thought of interchangeably, but the same question with 6 7 respect to anyone who worked at the HBC warehouse, have you spoken to them in preparation for this 8 deposition? 9 10 Α. Not in preparation for this deposition. (HBC-Carlson Exhibit 1 was marked.) 11 12 BY MR. ROTTINGHAUS: 13 Q. Let's take a look for a minute at 14 Exhibit 1, which I have passed out to your counsel 15 as well. I will represent to you that this was not given to me by the company, but I actually 16 went to LinkedIn, a source that a lot of us use 17 these days; right? 18 19 Α. Correct. 2.0 And I typed in your name, and Exhibit 1 is a document that came up. The first thing I 21 would like to do is make sure that Exhibit 1 --22 23 and, if we could, I might ask if we can split the 24 page so we can get the second page of Exhibit 1 on the screen as well for you. It may be on the 25

14 1 screen right in front of you. You can look at the hard copy or any screen you'd like to look at. 2 3 They should all be the same thing. Take a minute, if you need to, to look at 4 this, but does Exhibit 1 appear to you to be a document that indeed reflects you, Greg Carlson, 6 7 personally and some of the background you have had 8 in various capacities in your career? Α. 9 Yes. 10 Ο. Is Exhibit 1, to the best of your knowledge, a document you prepared and then in 11 12 some way uploaded or submitted to LinkedIn? 13 Α. Yes. Tell us a little bit about what LinkedIn 14 Ο. 15 is. LinkedIn, I quess it would be considered 16 a social media site but more geared towards 17 business, businesspeople and ways to connect with 18 them, find other people at other companies. I 19 2.0 just kind of look at it more as a social media 21 source. Some of us probably still refer to 22 23 documents with our background as r sum s. And in 24 some ways, does the LinkedIn social media site allow you to submit your r sum or your past work 25

15 1 experience? Yes. Most people kind of lay their page 2 out as a r sum , which is kind of how mine is laid 3 out. 4 Do you recall how long ago you prepared Exhibit 1? 6 7 Laying it out -- I've been on LinkedIn Α. for, I would say, over five years, probably closer 8 to ten. I'm not sure exactly when. And I've made 9 edits along the way. The most recent formatting 10 was probably -- I added the UPMC position. So it 11 12 was probably right around that time when I made 13 the most recent adjustment. In looking at the first page of 14 15 Exhibit 1, under experience for UPMC, I believe it says from March 2017 to the present, and then it 16 says one year, 11 months. 17 So it would appear to reflect at least from 18 the time you last put information in here up to 19 20 the present day; is that correct? 21 Α. Correct. And is it correct that you still do hold 22 23 the title of director of pharmacy MTM services at 24 UPMC Health Plan? 25 Α. Yes.

- Q. Do you work in the Pittsburgh area?
- A. Yes. I work in downtown Pittsburgh.
- Q. If we could go to the second page of this document, I'm going to start where it says Director of Pharmacy Sourcing. Actually, forgive me. I'm going to go kind of towards the bottom.

First of all, the education section, it appears that you obtained your Pharm.D. degree in 1998?

A. Yes.

- Q. And then from 1998 until 2007, tell us what you did.
- A. So in 1998 -- actually, in '97 I received my bachelor's degree in pharmacy. So I was a pharmacist, went on for another year. So from '97 I worked as a pharmacist for Osco Drug in Chicago, part of the Jewel-Osco chain, as a staff pharmacist.

And in 1999 I moved to Pittsburgh. I think
the end of March of 1999 moved to Pittsburgh and
started working with Giant Eagle at that point in
time as a pharmacist in the stores, in a role that
they called floater pharmacist where you would
work at any store that needed help covering
vacation times, maternity leaves, anything like

```
that. So I kind of worked all through the south region of Pittsburgh as a pharmacist.
```

2.0

- Q. To make sure I understand, that would be in the retail Giant Eagle stores if someone came to the pharmacy with a prescription or needed one filled, you would be the person we usually refer to as the pharmacist in the store?
- A. Correct. And in 2000 I started a role as pharmaceutical care coordinator -- it's more of a clinical role -- out of the stores, office based, corporate office based, and would go out and visit with patients at their store that they shopped at to review their medications.

So it was more of a sit-down typically in the cafeteria area of the store, and we would review their medications, looking for any kind of drug interactions, drugs they don't need, making recommendations to the physician based on their profile and educate them on their disease states.

So I did that for roughly about a year or so.

At that point, there was a position open for

manager of pharmacy services, and that role -- I

applied for that role, and I got it. It was a

promotion. And that role consisted of

manufacturer relations, vendor relations,

wholesaler relationship, and also dealt with marketing and other just tasks at corporate level.

- Q. Do you recall what year you took that position?
- A. 2001. At some point in 2001 is when I started that role and was in that role until the one that is listed on LinkedIn as district leader, pharmacy district leader. At the time I was in that role, it was called pharmacy specialist.

 It's the same thing as the pharmacy district leader today.
- Q. When you had the position as pharmacy specialist, which is now known as pharmacy district leader, did you work in the corporate office?
- A. It was more on the road based. So I covered a region. So I was responsible for anywhere from 25 to 35 stores at any given time.

 So I was assigned a region and was responsible for all the operations of the pharmacies for those stores.
- Q. Did you at any point in time have a region of Ohio as part of your region?
 - A. No. I never covered any Ohio stores.
 - Q. And from 2001 to 2007, you held that

title?

- A. 2005 to 2007 I was the pharmacy district leader. So I was the manager of pharmacy services from 2001 to 2005.
- Q. And then on Exhibit 1, where pharmacy district leader is listed from September 2005 to March 2007, there appear to be about five bullet point summaries of what your position entailed.
 - A. Yes.
- Q. Is that correct? You don't have to go through this in any particular order, but, again, I'm particularly interested in what you were doing in terms of monitoring pharmacy practices at that point in time.
- A. Well, we would do inspections of the pharmacies on a regular basis. We'd come in and we had a checklist, and we would go through that to make sure that the pharmacies were following proper procedure, all their paperwork was in line, the record keeping was in line.

We would monitor the stores' sales, their labor spend and look at all of that, and we'd review that with the pharmacy leader at that store.

Q. You mentioned that you would use a

```
20
 1
      checklist. Is that something you prepared or was
      that something that was prepared at corporate?
 2
 3
           Α.
                There was a corporate checklist that you
      would follow.
 4
                This may sound like a silly question,
      but why does it make sense to have a checklist
 6
 7
      when you're going to various stores and going
      through --
 8
                It just gave you something to, you
 9
      know -- it created a routine for you to do.
10
              Created a routine for you as the PDL or
11
12
      the pharmacy rep at that time?
13
           A.
                Yeah, yes.
                And also for the pharmacies to
14
15
      understand what the expectations were for them as
      well?
16
           A.
17
                Yes.
                And that's typical in most businesses;
18
      is that correct?
19
2.0
           Α.
                Yes.
21
                And then you, I think, mentioned that
      you wanted to make sure they were up to date and
22
23
      correctly doing their record keeping.
24
           Α.
                Yes.
                In a pharmacy it's important to keep
25
           Ο.
```

21 accurate records? 1 2. Α. Yes. 3 Ο. Why is that? Well, certain requirements are in place 4 Α. for state and federal laws. So I was just checking in on that. 6 7 And then you mentioned, I think, that Ο. along the checklist, you wanted to check and make 8 sure they were following proper procedures. 9 10 Yes. We would look at things like their workflow, how they were set up, were they 11 12 following what we recommended for the workflow of 13 the store. We would monitor the lines, how long were the lines. It could indicate whether or not 14 they were following proper workflow procedures. 15 It was a multitude of things. 16 Again, we don't need to get into the 17 details of them. But these workflow procedures 18 you're talking about, I assume those were 19 2.0 procedures that were somewhere written in writing to give quidance to your pharmacists? 21 22 I'm not certain. I can't remember as 23 far as what was in writing or not back in the 2005 24 timeframe. I can't really answer that one. Q. Was it -- and if you can't tell us, 25

22 1 that's fine. Was it your experience that when you worked with Giant Eagle, there were indeed some 2 policies that the company expected their 3 pharmacists to follow? 4 Α. Yes. And some of those policies were actually 6 7 written in writing to give guidance to the pharmacists? 8 Α. Yes. 9 10 And not only for the pharmacists, but it's your understanding and memory at the time 11 12 that there were also policies or procedures, if 13 that's what you would prefer to call them, that were in writing that dealt not only with pharmacy 14 15 services, but other aspects of the company as well? 16 Yes. There were many policies in place 17 Α. across the whole organization. 18 That's been consistent with your entire 19 20 career. You've seen companies that have policies 21 in place; correct? 22 Α. Yes. 23 And policies help provide guidance to 24 employees of the company? Generally, yes. There's policies. We 25 Α.

- have procedures. We have guidelines. So there's different classifications of what I would kind of consider a policy versus a guideline.
- Q. Sure. How do you differentiate between a policy and a guideline?
- A. Policies tend to be more HR driven. You know, they're meant from an HR perspective to be utilized versus guidelines. Within the profession of pharmacy, you provide guidelines to the pharmacists on how we would like them to operate. But there are, you know, professional judgment that will kind of supersede some of that.
- Q. Because any pharmacist who practices may have gone to school for a long time and learned a lot of information to help them develop expertise as a pharmacist?
- A. Yes.

- MR. BARNES: Object to the form to the extent you're asking him to speculate as to any pharmacist.
- 21 BY MR. ROTTINGHAUS:
 - Q. I don't want you to speculate. We'll focus on what you know. It's your understanding you personally went to school for a long time to earn the degree that you have in pharmacy;

24 1 correct? 2 Α. Yes. 3 Ο. And it's hard work? It wasn't easy. 4 Α. Any pharmacist, as you said I think, is Q. expected to use clinical judgment at times when 6 they practices as a pharmacist. 7 Α. 8 Yes. However, I think you also said that 9 10 there are times where guidelines might be written. They could be procedures. And you correct me if 11 12 I'm wrong, but guidelines might be written to 13 allow a pharmacist who is using his or her professional judgment to also understand what some 14 15 basic expectations are for any particular scenario? 16 MR. BARNES: Object to form. 17 THE WITNESS: I would just need more 18 specific on the question. 19 2.0 BY MR. ROTTINGHAUS: 21 Well, you tell me what type of Ο. 22 quidelines you remember being in place for 23 pharmacists between 2005 and 2007. 24 MR. BARNES: Tom, I'd just remind you that HBC didn't distribute any controlled 25

```
25
 1
      substance before November 2009.
                MR. ROTTINGHAUS: I'm just trying to
 2
 3
      build a little foundation. I understand the
      objection.
 4
                THE WITNESS: I can't recall. I mean,
      over the years I was with Giant Eagle, I know we
 6
 7
      had different procedures in place. This year
      particular, I couldn't tell you what exactly was
 8
      in place. It's a very difficult question to
 9
10
      answer looking back that far.
      BY MR. ROTTINGHAUS:
11
12
                Now, you just used the term procedures,
13
      and I really want to just make sure we're on the
14
      same page with what we're talking about.
15
           I think you mentioned that you consider
      policies to typically be HR, which I assume you
      mean human resources, driven.
17
           Α.
18
                Yes.
                Then you mentioned procedures and
19
20
      guidelines. Do you differentiate between
21
      procedures and guidelines?
                I mean, they're similar. I mean, some
22
23
      documents may call it one thing, one may call it
24
      another.
           Q. In your role as pharmacy district leader
25
```

```
27
      checklist or go through checklists with the
 1
      pharmacy teams; is that correct?
 2
 3
           Α.
                Yeah. That's a very generic term. It
      was just in there basically to say I would
 4
      oversee -- make sure they're following the process
      that we want them to, their customer service is up
 6
 7
      to par, their quality is up to par. So that
      encompasses really everything under pharmacy
 8
      practices.
 9
10
               And during that timeframe, were you also
      in any way responsible for reviewing written
11
12
      policies, procedures or quidelines that existed
13
      for the pharmacies?
14
                MR. BARNES: Same objection.
15
                THE WITNESS: When you say review, do
      you mean read? Because, I mean, reading, yes.
16
      Formulating at this time, no.
17
      BY MR. ROTTINGHAUS:
18
                That's a good point. It's my
19
20
      understanding you were not responsible all the way
21
      up to 2007 for formulating any policies,
      procedures or quidelines.
22
23
                Correct, in that position.
24
               However, I think what you're saying is
      you may have at times reviewed certain written
25
```

```
28
      policies, procedures or guidelines, but sitting
 1
      here today, you couldn't tell us exactly what you
 2
      did?
 3
           Α.
                No.
 4
                And sitting here today, is it fair to
      say that you can't really even recall what
 6
 7
      specific policies, procedures or quidelines were
      in writing up through March of 2007 for Giant
 8
      Eagle?
 9
10
                MR. BARNES: Same objection.
                THE WITNESS: Yeah. I couldn't tell you
11
12
      specific policies from 2005 or through 2007.
      BY MR. ROTTINGHAUS:
13
                We're going to jump forward here in just
14
      a second to your new position you took in April of
15
      2007.
16
           Do you feel like we have covered all of the
17
      responsibilities and duties you fulfilled for
18
      Giant Eagle as a pharmacy district leader from
19
20
      September 2005 through March 2007 just generally?
21
                MR. BARNES: Are you saying in addition
      to what's written on his LinkedIn profile?
22
23
                MR. ROTTINGHAUS: Yeah.
24
      BY MR. ROTTINGHAUS:
                I mean, obviously, we're looking at your
25
           Ο.
```

- LinkedIn profile. I'm not asking for details. I understand it was several years ago and you probably don't remember every detail of every day, and I certainly don't expect that.
 - A. Yeah. I mean, generally speaking, yes, there were other things that would pop up day to day. If anything happened at the store, it was something I had to deal with.
 - Q. And correct me if I'm wrong. I think you said there were maybe, give or take, but around 25 to 35 stores you were responsible for during that timeframe?
 - A. Yes.

2.0

- Q. Were they in the greater Pittsburgh area?
- A. Most of them were in the southern region of Pittsburgh, and that actually extended down to Morgantown, West Virginia. But then there were times where I would cover other regions if there was a leave of absence. I do recall one time I had the Beaver Valley area. But it was generally around the Pittsburgh market.
- Q. It's my understanding that Giant Eagle during the timeframe when you worked there had pharmacies in five different states.

30 Α. Yeah, up to five at the time I worked 1 there. 2 Pennsylvania? 3 Q. Ohio, West Virginia, Maryland and 4 Α. Indiana. During this timeframe we've been talking 6 about, 2005 to 2007, you were primarily covering 7 stores in Pennsylvania but maybe some stores in 8 West Virginia? 9 10 Α. Yeah, West Virginia as well. Q. Any other states? 11 12 Α. No. 13 Q. Let's move right above this area to your title of director of pharmacy sourcing from 14 April 2007 to April 2012. If it's hard to read on 15 that hard copy, again, it's on the screen if 16 that's helpful to you. 17 I see that you have also kind of listed some 18 bullet points that give a general summary for what 19 20 you did during that timeframe. 21 Α. Yes. 22 If you can just in your own words 23 describe for us what your position entailed as director of pharmacy sourcing from April of 2007 24 to April of 2012. 25

A. In that role, the primary role was to find cost savings through sourcing. So it was including anything that the pharmacy would purchase. It could include supplies such as bags, vials, anything like that, or medications. So it could be through our wholesaler contract. There was pricing established within each contract. So I was involved in those negotiations as well as finding any other ways to save money on any product.

- Q. I see that -- first of all, the point you mentioned that you negotiated the wholesaler contract to save \$16 million annually, was that as part of a team, or was that just you individually who was involved in that negotiation?
- A. There were people involved other than myself. I was kind of like the point person, but we did have a team working on that.
- Q. Do you recall whether that contract entailed, among other things, controlled substances?
- A. With the wholesaler we were purchasing controlled substances. So it would entail that, nothing broken out specifically for that.
 - Q. We're going to be talking about

```
32
      controlled substances at various times obviously
 1
      today. Specifically, I'm going to be talking
 2
 3
      about hydrocodone combination products. Is that a
      term that's familiar with you?
 4
           Α.
                Yes.
                Sometimes they're referred to, I think,
 6
      as HCPs for short; is that correct?
 7
                Yeah. I mean, I never referred to it
           Α.
 8
      that way, but I guess you could go there.
 9
10
                I'll try not to use that term. If I do,
      feel free to remind me you don't know what I'm
11
12
      talking about. But I'm probably going to be --
13
           Α.
                HCP meaning hydrocodone combination
14
      products?
15
           Q.
                Yes, or combination products.
               Combination products. Okay.
16
                I think it's probably the same thing
17
      we're talking about.
18
           In April 2007 when you negotiated this
19
20
      wholesaler contract, do you know whether that also
      entailed hydrocodone combination products?
21
22
           Α.
                It would have been included in the
23
      general pricing structure.
24
           Q. I should have told you. You probably
      know this. At times people may have a concern
25
```

33 1 about a question I ask, and it may be well founded, but nobody is trying to interrupt us, but 2 I'll try to let them finish their objection. If 3 you can, let them try to get their objection in as 4 well. Α. 6 Okay. 7 I see in the second bullet you state Ο. that you at that time at least, it says, opened 8 generic prescription drug warehouse for pharmacy 9 10 with estimated annual savings of over \$20 million by purchasing direct from the manufacturer. 11 12 I'm assuming, and I could be incorrect, but 13 I'm assuming this is the HBC warehouse. Yes. That would be the HBC warehouse. 14 15 Were you involved in starting that Q. warehouse from the ground up? 16 Α. 17 Yes. Who else at the company was involved? 18 Q. Well, there were several people 19 20 involved. It was kind of a team project to get it up and running. 21 22 MR. BARNES: Excuse me. Tom, for 23 clarification, you mean as a brand new warehouse 24 opening for the first time and doing any business whatsoever or just with respect to 25


34 1 pharmaceuticals? MR. ROTTINGHAUS: That's a good 2 3 question. Let's clarify. BY MR. ROTTINGHAUS: 4 When did HBC warehouse open, not just with respect to controlled substances or 6 pharmaceuticals, but when did that warehouse open 7 up? 8 I don't know the specific dates. 9 10 goes back. It predates me. We purchased actually FoxMeyer. My understanding, it was a FoxMeyer 11 12 warehouse that McKesson acquired. And we ran it 13 from there as HBC at that point. I think that was pre-2000. I don't have specific dates. 14 15 So I know HBC had been operating for a while before. All we did -- when I say open generic 16 warehouses, we isolated a spot within the 17 warehouse, secured it and utilized that. It was 18 just an add-on to the warehouse. 19 2.0 Q. And when you say secured it, you're 21 talking about putting security controls in place 22 because, among other things, some of the 23 medications that were going to be coming into and 24 out of that warehouse were controlled substances? A. Not at this time. When we opened it, it 25

35 was really finding a location that was isolated 1 because even prescription drugs need to be 2 isolated securely, whether it's Amoxicillin or 3 Simvastatin, cholesterol medications. So it was 4 really just finding a location that had secure walls, doors, that we could have security access 6 7 to so we knew who was going to go in that specific room. At the time we opened, that was our 8 thought. 9 10 Ο. Do you recall when HBC first started distributing hydrocodone combination products? 11 12 Α. I believe, from recollection, it was 13 2009. It was towards the end of 2009. So it was either the end of 2009 or early 2010 after we 14 15 received our DEA license. And then it continued to do so until 16 2014 as I understand it. 17 Α. Correct. 18 So when you were first involved in 19 20 starting the HBC warehouse, it predated the DEA 21 license to distribute hydrocodone combination products, among other things? 22 23 Α. Yes. 24 Q. Let's go to that last bullet under your title of director of pharmacy sourcing from 2007 25

```
36
 1
      to 2012. It states that you negotiated with brand
      drug manufacturers to secure funding for
 2
      pharmacist education, in-store promotions and
 3
      patient compliance programs.
 4
           Do you remember what patient compliance
      programs you were involved in?
 6
 7
           Α.
                I'm trying to remember. It probably
      didn't happen that much in that timeframe. That
 8
      was more we would do medication adherence letters.
 9
      We call them refill reminder letters. That was
10
      probably more towards the manager pharmacy
11
12
      services role. That bullet may be a little bit
13
      misplaced there as far as that goes.
           The only compliance programs were we would
14
      send letters on behalf of -- the manufacturers
15
      would help, you know, fund the cost of the letter
16
      going out, but it was really for the patients'
17
      behalf. It was typically like maintenance
18
19
      medications, like a cholesterol medication,
2.0
      something like that.
21
22
23
24
25
```







40 When you went to work each day, you 1 2 weren't going into that warehouse every day? 3 Α. No. Are you able to tell us approximately 4 how many times you visited the HBC warehouse during your entire tenure with the Giant Eagle 6 7 company? MR. BARNES: Object to form to the 8 extent it asks for anything prior to 2009. 9 10 THE WITNESS: I can't give you a number, an accurate number. I probably couldn't even 11 12 estimate it at this point. 13 BY MR. ROTTINGHAUS: Let's focus between 2009 and 2014. Do 14 you think you visited the HBC warehouse on at 15 least a yearly basis one time a year? 16 I would say a yearly basis, yes. 17 Α. What would be the purpose for going 18 physically to the warehouse? 19 2.0 Α. Sometimes it was just to meet with the 21 team there to see how things were going, to see if 22 anything needed to be changed. Anything could 23 have come up as far as do we need additional 24 shelving, do we need new shelving, are we going to try new processes at the warehouse and they wanted 25

41 to either show us or talk to us about it. 1 2 So it could have been any kind of meeting 3 such as that. Q. Do you remember any particular 4 individuals who you considered to be a part of the team at HBC warehouse? 6 7 Α. Yes. I do recall some folks there that were -- that I would just talk to on a regular 8 basis. Andy Zalewski was early on one of the team 9 members I would talk to. I don't remember when he 10 left. Christy Hart was one of the main people 11 12 there, too, that I would talk to. And then Walt 13 Durr and Matt Rogos. At another point in time, Matt Rogos was another individual. 14 15 Do you remember between 2009 and 2014 what Walter Durr's title was for HBC? 16 17 I don't know specifically during that time because I know Walt had moved. There were 18 some changes in the wholesale or the warehouse 19 20 level team members where they -- I know Walt got 21 additional responsibilities at one point in time. 22 So I don't remember at that time what Walt's 23 position was. I'm assuming he was in charge of 24 HBC, but I can't answer that accurately. Q. What about Mr. Rogos, do you remember 25

what he did at HBC?

- A. There was a point in time where he came in after Andy left. Again, timeline-wise, I'm a little fuzzy on when Matt was there. So he was in charge of the facility at one point in time, the HBC facility. And then, you know, Christy kind of reported to him.
- Q. I understand Giant Eagle was a big company, and it looks like you wore different hats for the company, for lack of a better term, at different points in time.

I'm not trying to make you an expert in something you don't feel like you have the expertise to tell us about. So if I ask you questions about HBC or some aspect of HBC that you don't feel like you're the right person to answer it, I respect that. Just let us know.

- A. Okay.
- Q. Having said that, I'm going to ask you some questions to see if you do know.

Between 2009 and 2014, do you believe you were the person who overall oversaw operations at HBC?

- A. I did not oversee operations at HBC.
- Q. At any point in time all the way up to


43 2016, do you believe you were the person who 1 oversaw operations at HBC? 2 3 A. Not at an operations level, no. At any level? 4 Ο. I was involved with decision making regarding HBC but not from an operational 6 7 standpoint. Correct me if I'm wrong, but as I 8 understand it, because you were involved in 9 10 contracts that were being executed with various vendors or manufacturers, you would have been 11 12 involved at least indirectly with what HBC had 13 coming into its warehouse and going out of its warehouse? 14 15 Yes. As far as product choice, yeah, it would come from me or my team as far as that goes. 16 But in terms of day-to-day operations, 17 Q. were you the person who someone at HBC would call 18 if they needed supervisory authority to do 19 2.0 something? 21 If there was a question regarding something related to the store level, then it 22 23 could come up through me. What if it related to HBC as the 24 Q. distributor at that level, were you the person 25

44 someone would contact with a question about, hey, 1 can we distribute this medication to store number 2 3 whatsoever? There were times where questions would 4 come up about a specific order and it was asked. 5 So they could ask me that question. 6 7 I'm trying in my mind to get a better Ο. understanding of, for lack of a better term, a 8 chain of command if there was one. Let me ask you 9 10 this. If you can tell me, great. If you can't, just let me know. 11 12 Between 2009 and 2012, do you believe there 13 was an individual at Giant Eagle who was in charge and had the ultimate supervisory authority at HBC? 14 15 Yes. There was somebody in charge at 16 HBC. 17 Q. Was it you? From a supervisory perspective? 18 Α. 19 Q. Yes. 20 Α. No. I did not do any team member reviews for anybody at HBC. I wouldn't be 21 22 involved in disciplining anybody at HBC. Nobody 23 reported to me from an organizational structure. 24 Q. You said it better than I asked it. I 25 appreciate that.

45 Who was the individual who would review 1 performance of individuals at HBC? 2 3 I can't answer that question. I'm not certain. 4 With respect to if there was a need to discipline someone at HBC warehouse for any 6 7 particular reason, do you know who that person would be? 8 It would have gone up through their 10 chain of command at HBC, the org chart at any date in time. So it would depend on who was in charge 11 12 of the facility. Like I said, who was in charge 13 did change a couple times through the years, but I couldn't tell you when or who exactly. So I think 14 it would have to be -- I don't think I can answer 15 16 that one for you accurately. That's fine. I have to confess to you I 17 Q. don't have an org chart for HBC. I do have one, I 18 think, for at least as of 2014 for Giant Eagle. 19 2.0 And maybe that's the same. 21 (HBC-Carlson Exhibit 2 was marked.) BY MR. ROTTINGHAUS: 22 23 That's Exhibit 2, and we'll look at that 24 in a minute, but if you want to look at that to answer any of these questions, you can feel free 25

46 1 to do so. We'll come back to it though. Were you the individual who oversaw HBC's 2 3 compliance as a distributor of controlled substances between 2009 and 2014? 4 Well, the compliance did fall under me as far as we did have a team looking at compliance 6 also, but, I mean, ultimately, as far as the -- if 7 you want to refer to an exhibit at all. But at 8 this point in time, compliance would have fallen 9 10 under me. Ο. Between 2009 and 2014? 11 This is '14, but yes. 12 Α. 13 Q. And you can feel free to look at an 14 organizational chart if you need to, but I'm not 15 asking you to go off that. I'm really wanting to know what Mr. Carlson remembers. If you need to 16 look at that again, that's fine. 17 So let me make sure I understand because 18 compliance is kind of a general term, isn't it? 19 2.0 Α. Right. 21 What does compliance mean to you? Well, following all the rules and 22 23 regulations put in place, whether it's federal 24 government laws or state laws. Q. So as I understand it, whatever state a 25

47 1 warehouse that distributes medications is in, it has to comply with that state's laws? 2 3 Α. Correct. And then as you mentioned, there are 4 also often laws at a federal level or regulations at a federal level that must be followed as well? 6 7 Α. Yes. And you probably have some familiarity 8 with what's known as the Controlled Substances 9 10 Act? 11 Α. Yes. 12 And is it your understanding that the 13 Controlled Substances Act has some requirements that distributors of controlled substances must 14 15 follow regardless of what state they're practicing in? 16 Α. 17 Yes. You probably got some of the basic 18 background about the Controlled Substances Act in 19 20 pharmacy school. 21 Α. Yes. And then you probably learned some of 22 23 that on the job as well? 24 Α. Yes. Have you individually ever attended any 25 Ο.










```
52
 1
 2
 3
                (HBC-Carlson Exhibit 3 was marked.)
 4
      BY MR. ROTTINGHAUS:
                I have a hard time with that word.
 6
 7
      Let's refer for a minute to Exhibit 3, but we're
      going to come back to Exhibit 1. Okay?
 8
           A.
 9
                Okay.
10
                Let's look at Exhibit 3, which is
      general number 010. So that you know,
11
12
      Mr. Carlson, I'm going to reference sometimes
13
      general numbers. It's really just for the person
      who's putting all of these up on the screen for
14
15
      us. Okay?
           Do you have Exhibit 3 in front of you?
16
           Α.
17
                Yes.
                I think this is a portion, not the
18
      entirety, of the Code of Federal Regulations
19
20
      dealing with registration of manufacturers,
      distributors and dispensers of controlled
21
22
      substances, and the specific section that
23
      Exhibit 3 references is a section you've probably
24
      heard of or referred to before, Section 1301.74.
           Are you familiar with this section?
25
```

53 Α. I'm sure I've read it at some point in 1 time. 2 3 Q. Specifically I'd like to direct your attention to subsection (b) of 1301.74. 4 MR. BARNES: Tom, for the record, I'm going to object to this exhibit as being just one 6 7 subpart of the security requirement in the Code of Federal Regulations. Not only have you just taken 8 one part. You haven't given him the 1301.71 and 9 10 the other regs of which this is a part of. BY MR. ROTTINGHAUS: 11 12 Q. Are you with me? 13 Α. Yes. I'm going to read subsection (b). You 14 15 tell me if I've read it incorrectly. "The registrant shall design and operate a system to 16 disclose to the registrant suspicious orders of 17 controlled substances. The registrant shall 18 inform the field division office of the 19 20 Administration in his area of suspicious orders when discovered by the registrant. Suspicious 21 22 orders include orders of unusual size, orders 23 deviating substantially from a normal pattern and 24 orders of unusual frequency." Did I read that correctly? 25































































```
85
 1
      BY MR. ROTTINGHAUS:
                Is it ever a good idea to put policies
 2
 3
      in writing, in your opinion?
                MR. BARNES: Same objection.
 4
                THE WITNESS: I don't think there's
      anything wrong with putting a policy in place.
 6
      BY MR. ROTTINGHAUS:
 7
           Q. You think sometimes it's a good idea?
 8
                MR. BARNES: Object to form.
 9
10
                THE WITNESS: I think it depends on your
      organization. If the organization runs off
11
12
      policies, then that's what they would put
13
      together.
      BY MR. ROTTINGHAUS:
14
           Q. Did HBC run off policies between 2009
15
      and 2014?
16
           A. We ran off of procedures.
17
               Some of those procedures were put in
18
      writing in the form of a policy; correct?
19
2.0
                If you could point to one, I can say yes
      or no. I don't know.
21
22
                If you don't know, that's fine.
23
           A.
               Yeah. I don't know.
24
           Q. And you don't know sitting here today as
      the person responsible for making sure the company
25
```

```
86
      was complying with the Controlled Substances Act
 1
      between 2009 and 2014 whether HBC had any policies
 2
 3
      in writing during that timeframe?
                MR. BARNES: Object to form.
 4
                THE WITNESS: They had procedures in
      writing.
 6
      BY MR. ROTTINGHAUS:
 7
               Now you're using procedures, not
 8
 9
      policies. So I want to make sure I'm not getting
10
      confused.
                It's a definition from a Giant Eagle
11
12
      definition standpoint. So you can define policies
13
      and procedures however you want. We had
      procedures documented.
14
15
           When we went to get our DEA license, we had
      to have procedures documented. Otherwise, they
17
      would not have approved. The DEA approved our
      facility to be licensed. We had to have the
18
      required documentation and procedures put together
19
20
      on paper, and we showed them to the DEA officers
21
      who came in and inspected the facility prior to
      using it. And all of our procedures matched up
22
23
      with the Controlled Substances Act.
24
           Q.
               And these are in writing?
           A. They were in writing.
25
```





































































































137 THE WITNESS: Can you restate the 1 2 question? BY MR. ROTTINGHAUS: 3 Sure. Let me back it up. We've been 4 Q. looking at an email from August of '15. But I'm going to kind of focus a little bit off of that 6 date. 7 From 2009 to 2014, at some point in time, did 8 you become aware that relying on thresholds of 9 10 shipments of hydrocodone combination products from the HBC warehouse was not sufficient to satisfy 11 the duties of a distributor under the Controlled 12 13 Substances Act? MR. BARNES: Object to form. 14 15 THE WITNESS: I mean, there's nothing in the regulations, to my knowledge, that 16 specifically say thresholds. I can't answer that 17 question because my thought process wasn't like 18 that. Our system didn't only rely on thresholds 19 2.0 anyway. It included other safeguards and 21 measures. So I would say nothing was new to my 22 knowledge of the process. 23 BY MR. ROTTINGHAUS: 24 Let's talk about what your system did use. You said it didn't just rely on thresholds. 25

Tell us what your system did rely on to identify any suspicious orders between 2009 and 2014.

A. We have a number of systems, had a number of systems in place at the time. Some of those are around general reporting and monitoring movement reports on a daily basis. Some included safeguards where unusual quantities were caught prior to going out.

So if anything was a large order, outside of the norm, it was immediately stopped and red flags were thrown out. Questions were asked as far as the validity of that order, and it wasn't released until it was investigated.

The stores had a process to check in the orders bottle by bottle. They had other safeguards in place around safe dispensing of controlled substances to the patients, looking for other red flags as far as the dispensing process. So those are some of the things. I can't recall every piece of it.

Q. I wrote down a couple of things that I want to ask you about in follow-up.

First of all, are you talking about the timeframe of 2009 to 2014 when you're referencing these different processes in place?

- A. Yes. We always had processes in place from the beginning. It was mainly modifications along the way to the process.
- Q. And these processes as you described them, were they put in place in an attempt to make sure that HBC warehouse was complying with its responsibilities as a distributor under the Controlled Substances Act?

MR. BARNES: Object to form.

THE WITNESS: We were always complying with the rules. We were trying to make our process better, more efficient. So it wasn't a matter of are we compliant. It was a matter of is our process working the most efficient way it can. Examples of that is removing some of the manual components to that, automating it with reporting or other systems.

BY MR. ROTTINGHAUS:

Q. Were these processes you've just talked about, monitoring movement reports, managing unusual quantities, stopping them, those processes we were just talking about, were they put in place as part of an effort to design and operate a system to disclose orders of controlled substances that might end up being suspicious orders?

140 1 MR. BARNES: Object to form. THE WITNESS: My answer would be that 2 3 they were put in place to meet the requirements of the Act. So if that's what was in the Act, that's 4 part of the reason why they were put in place. BY MR. ROTTINGHAUS: 6 7 When you say the Act, you're talking Ο. about the Controlled Substances Act? 8 Controlled Substances Act, yes. Α. 10 Do you know -- well, first of all, let me ask you this with respect to that. You said 11 12 monitoring movement reports? 13 Α. Yes. 14 In preparing for this deposition, have you seen one of those reports? 15 I mean, I saw them years ago, but I have 16 not seen any movement reports in preparation for 17 this. 18 19 Are these the reports that are also 20 called daily control reports? 21 I don't believe those were -- I mean, we had -- basically we had buyer reports, for 22 23 example. So they were just reports that were 24 printed out daily. I might have a stack of them on my desk. It would show you daily movement, 25

141 1 weekly movement, monthly movement, things like that. 2 3 Ο. Were you personally tasked with the responsibility to review the daily movement 4 reports to identify any movements of suspicious quantities of substances, or was there some other 6 7 place to assist you in that? MR. BARNES: Object to form. 8 9 THE WITNESS: There were other systems. 10 I can't remember which reports that would flag certain things. The one I was speaking of was 11 12 just a general second level safeguard where I can 13 see if any movements were out of line from 14 previous history. 15 But there were other reports -- I can't think of the names of those reports -- that were out 16 there that would look at movements of therapeutic 17 categories of drugs specifically. 18 BY MR. ROTTINGHAUS: 19 2.0 Q. So you at this point in time, from 2009 21 to 2014, sometime during that timeframe, you 22 became a senior director of pharmacy? 23 Α. Yes. 24 Q. And when you became the senior director of pharmacy, were you overseeing all 200 something 25

142 Giant Eagle stores? 1 No, not the stores. I was overseeing 2 3 all of corporate functions at that point. So Anthony Mollica was still in charge of the 4 operations of the stores. I was responsible for the contract management of any vendors, the 6 7 managed care side, which is the insurance 8 contracting piece of it kind of rolled up underneath me as well. So it was more at that 9 10 level. And I just want to make sure I 11 12 understand. During this timeframe from 2009 to 13 2014, you're telling us that one of the processes in place was you would get a sheet of daily 14 15 movement of all of your medications, including controlled substances, and you would personally 16 look through that to try to identify any orders 17 that seemed out of the ordinary? 18 19 Α. We had buyers. 20 Q. First of all, am I correct in what I said? If I'm not, just correct me. 21 22 Oh, no, I mean, I didn't daily look at those reports. We had buyers in place at that 23 24 time. We had a category manager in place at the time. So they would use that to generate their --25

143 1 as part of their reordering process. So when we reviewed that, they could also see any out of the 2 3 norm patterns in that process. Q. And you're saying you're one of the 4 individuals that was reviewing and tasked and responsible for reviewing for any out of the norm 6 7 patterns? 8 I didn't. When you mentioned senior director of pharmacy, no, I was not reviewing the 9 10 reports at that time. Ο. And that would have been between 2005 --11 12 Α. Right. 13 Q. I'm sorry. 2007 and 2012. No senior director of pharmacy. 14 A. 15 Q. 2012 to 2014. 16 A. Correct. 17 Q. You were not doing so? I was not reviewing the daily reports 18 back at that point. 19 2.0 Who was reviewing the daily reports at 21 that time, if anyone? 22 Kris Remas would have been reviewing 23 reports as part of -- again, our daily process was 24 to review the reports. Q. Now, when those reports would get 25











149 THE WITNESS: Not necessarily. 1 BY MR. ROTTINGHAUS: 2 3 Q. So you don't think it would be a good idea? 4 I don't think -- looking back, I don't know if it would be a good idea or a bad idea. We 6 didn't have any issue with it. We were very good 7 with the process. Never had any large orders slip 8 through. So I think the procedure that we had in 9 10 place was sufficient. You say you never had any large orders 11 12 slip through. What did you consider to be a large 13 order? 14 It depended on the product. You couldn't make a determination broadly. It was 15 what's the normal for this. That would kind of 16 classify as, you know, whatever the 17 classifications are as far as a large order. 18 You understood that as early as 2008, 19 20 some companies, some distributors were using 21 thresholds at least to help them identify some orders that might be out of the ordinary? 22 23 MR. BARNES: Object to form. Lack of 24 relevance. THE WITNESS: Timeline-wise I'm not 25

150 1 certain, but I do remember threshold emails coming from McKesson. 2 BY MR. ROTTINGHAUS: 3 And actually threshold criteria started 4 Q. to get set for HBC as of 2013; is that right? There was a report created, an automated 6 7 report created at that time. 8 Q. Whose idea was it to create that report? I'm not sure who came up with the idea, 9 10 but it was a team that kind of worked on how do we come up with a process to do that. 11 12 Q. Why was the team trying to come up with 13 a process to identify thresholds at HBC warehouse? We were trying to enhance and improve 14 15 our process along the way. The process of identifying orders that 16 might be in excess of ordinary? 17 It would be targeting not orders 18 specifically. Thresholds don't catch one order. 19 2.0 Thresholds capture patterns of orders. So one large is not, unless it exceeds the threshold, is 21 22 not going to be caught by the threshold. 23 What if it exceeded the threshold, what 24 did you expect to happen? 25 The order would be investigated. Α.

Q. How would it be investigated?

2.0

- A. There would be a number of people that would find out what was going on with that store in particular that would do -- down at the PDL level, district leader level investigating what was going on at that particular store.
- Q. So this level started below you where the investigation would start?
- A. Below me and the operations department would go and look at what's going on in the store.
- Q. That's what I want to understand, is what your system was, who the people were that were eyeing these threshold reports and then reporting to whoever they reported to if there were orders exceeding thresholds and then what due diligence was done.
- A. So the overall security efforts of the, you know -- to meet the needs of this particular act or regulation encompassed many different parts of the whole process. So it would be -- we looked at ourselves as a self distributor. We had owned the product, and we're basically handing it off to another location within our chain.
- Unlike a wholesaler, which is selling to a new customer, a different customer, self

```
152
 1
      distribution, we knew our customers because they
      were us. So we were very familiar with our
 2
 3
      customers. We knew exactly what was going on.
      Each of these prescriptions were dispensed with a
 4
      valid prescription. So those were kind of the
      added security measures that met the needs of the
 6
 7
      requirement.
 8
                Are you able to sit here under oath
      today and tell us that every one of the
 9
10
      prescriptions that HBC warehouse filled were
      filled with a valid prescription?
11
12
                MR. BARNES: Object to form.
13
                THE WITNESS: The HBC warehouse filled?
      BY MR. ROTTINGHAUS:
14
15
           Q.
                Yes.
                You mean the product coming from HBC
16
      warehouse?
17
18
           Q.
                Yes.
                I can't state, you know, something like
19
20
      that.
21
                I thought I heard you say that. I
      understand that you can't say that. I'm just
22
23
      wondering -- if you're able to say it, I wonder
24
      how.
           A. We act under the guise that our process
25
```

























































































197 Α. 1 No. You don't think written documentation of 2 Q. 3 an investigation is required or a good idea for a store? 4 MR. BARNES: Object to form. THE WITNESS: We followed whatever the 6 7 requirement of the DEA was in place. So there was 8 no record keeping requirements as part of the provision. So it wasn't something that we had 9 10 done. BY MR. ROTTINGHAUS: 11 12 Do you think it's a good idea for a 13 company like HBC to document what steps it's taking to attempt to comply with the law? 14 MR. BARNES: Object to form. 15 THE WITNESS: I haven't really thought 16 about it. I don't have an opinion on that. 17 BY MR. ROTTINGHAUS: 18 So between 2009 and 2014, you never gave 19 20 any thought to whether if there is an 21 investigation taking place for an order that's 22 exceeding a threshold limit, we should document in 23 some way what steps we are taking to make sure 24 that it's not a suspicious order? We had tight controls in place that 25 Α.

198 followed the full security measures of this, not 1 just 1301.74, but all of 1301. So this one small 2 3 subset was not our entire process. So we were very confident and comfortable 4 that we had one of the best systems in place to monitor it. 6 7 What were the tight controls in place to Ο. on a daily basis follow up and make sure that any 8 orders that were deemed to be in excess of 10 thresholds were not suspicious orders before they got shipped? Tell me about that tight process. 11 12 A. So when you say they were suspicious 13 orders --Q. Nope, I didn't. Let's listen to my 14 question. If I did, I apologize. I didn't mean 15 16 to. What was this tight process you've just told 17 us about? Well, let me ask it this way: Would 18 you agree that in order for this process to be 19 2.0 tight, whenever there was an order that exceeded the threshold limits, someone at HBC needed to 21 take some steps to find out why that order was 22 23 exceeding threshold limits? 24 MR. BARNES: Object to form. Calls for speculation. 25

```
199
                THE WITNESS: You're asking if someone
 1
      at HBC had to find out if it was a suspicious
 2
      order based on thresholds?
 3
      BY MR. ROTTINGHAUS:
 4
                Do you believe they should have?
                MR. BARNES: HBC or Giant Eagle?
 6
 7
                MR. ROTTINGHAUS: HBC.
                THE WITNESS: Well, HBC was -- the
 8
      reporting was all done at corporate level.
 9
10
      BY MR. ROTTINGHAUS:
               Well, wherever, let me ask you this: Do
11
12
      you believe that in order to keep a tight process
13
      in place -- I think you used the term we had a
      tight process.
14
15
           Α.
                Um-hum.
16
                In order to maintain a tight process
      between 2009 and 2014, don't you agree that it
17
      would have been a good idea to document what steps
18
      were being taken to follow up on any orders that
19
20
      exceeded thresholds for hydrocodone combination
21
      products?
22
                MR. BARNES: Object to form. Asked and
23
      answered.
24
                THE WITNESS: I don't think -- I don't
      see the benefit of documentation.
25
```

BY MR. ROTTINGHAUS:

- Q. Would one benefit of the documentation be the ability to show any regulatory body that HBC did indeed take steps to maintain a system, to implement, design and operate a system to disclose the presence of suspicious orders?
- A. When we opened HBC, we received our DEA, we were inspected by the DEA. They came in. They looked at all of our security features related to this Controlled Substances Act, looked at all of our processes.

Our security, according to them, fit all requirements, all the needed necessary steps. We were acting upon that. There was nothing in the provision that said we had to keep documentation for any period of time on any investigation.

We did our process. If there was any suspicion come up, we investigated it thoroughly, made our decision. And I can't even think of a time where we -- maybe there was a couple, but not that I can recall, an example when there was a suspicious order that we actually defined. I'm not saying it didn't happen, but I can't recall an example.

MR. ROTTINGHAUS: Object and move to

201 strike as nonresponsive. 1 BY MR. ROTTINGHAUS: 2 3 Q. I'm going to ask you a question, and if you can tell me "yes" or "no," I would appreciate 4 it. And if you can't, that's fine. Just let me know that you can't. Okay? 6 7 Α. Okay. And then you can explain why you can't. 8 Don't you think it would have been a good 9 10 idea between 2009 and 2014 for someone at either Giant Eagle or HBC to document any steps that were 11 12 taken to follow up on any orders that exceeded 13 thresholds and to show what due diligence was done to determine that they were not indeed suspicious 14 15 orders? MR. BARNES: Objection. Asked and 16 answered I think at least twice. 17 BY MR. ROTTINGHAUS: 18 "Yes" or "no," if you can. If not --19 Q. 20 Α. Do I think it would be a good idea? 21 Ο. Yes. 22 Α. No. 23 If we look at this policy, Exhibit 24, 24 if we can go to the second page of it -- actually, forgive me. Let's go back to the first page, the 25



































218 1 security requirement regulation. Are you familiar with that regulation? 2 Α. I have reviewed it before. 3 That regulation requires applicants and Q. 4 registrants to provide effective controls and 5 procedures to guard against theft and diversion of 6 7 controlled substances. Does that refresh your recollection? 8 Α. Yes. 9 Did Giant Eagle in the entire time that 10 Q. you were there meet this regulation? 11 MR. ROTTINGHAUS: Objection. Form; 12 insufficient foundation. 13 THE WITNESS: Yes. 14 BY MR. BARNES: 15 16 17 18 19 20 21 22 23 24 25







222 1 did you understand that to include an overall evaluation of the adequacy of the controls at the 2 HBC and store levels? 3 Α. Yes. 4 Do you understand that the regulation that you were shown by plaintiffs' counsel is just 6 one small aspect of the overall security 7 requirement? 8 Α. Correct, yes. 10 And do you understand that 1301.74 requires that HBC operated a system to disclose 11 suspicious orders? 12 13 Α. Yes. Did you ever understand it to require 14 15 any type of formulaic or threshold system? Α. 16 No. At the warehouse level, I just want to 17 explore what you do understand. You mentioned 18 cages, things of that nature. 19 2.0 Were these control IIIs, IVs, and Vs kept in locked cages? 21 22 Yes, per the DEA requirements of 23 specifically around the cage. You said the DEA actually reviewed the 24 Q. HBC security system before it opened and started 25

223 distributing control IIIs, IVs, and Vs? 1 Yes, before they approved our DEA 2 3 license. And did they come in from time to time 4 Q. to reaudit and inspect? Α. Yes. 6 7 MR. ROTTINGHAUS: Objection. Leading. BY MR. BARNES: 8 At any time, did the DEA ever advise HBC 9 10 that there was anything lacking in their control system? 11 12 MR. ROTTINGHAUS: Objection. 13 Foundation. THE WITNESS: There was nothing pointed 14 out within our security measures that didn't meet 15 the requirements. 16 BY MR. BARNES: 17 Did Giant Eagle ever distribute to 18 internet pharmacies? 19 2.0 Α. No. 21 Ο. By Giant Eagle I'm including HBC. No, we did not. 22 A. 23 But you've also told us that you don't 24 really know the details -- you said the pickers were regulated in terms of access to the cages; is 25

```
224
 1
      that right?
           Α.
 2
                Yes.
 3
           Ο.
                But the detailed procedures of how they
      actually did their picking and the forms they
 4
      filled out, that wasn't part of your job?
           Α.
                No, it was not.
 6
                Were inventories conducted at HBC?
 7
           Ο.
           Α.
                Yes.
 8
                Regular inventories?
 9
           Q.
10
           Α.
                Yes.
                Was the HBC warehouse overseen by Giant
11
           Q.
12
      Eagle's internal audit and accounting department?
13
                MR. ROTTINGHAUS: Objection. Leading.
                THE WITNESS: Yes.
14
15
      BY MR. BARNES:
                You were asked a lot of questions today
16
      about the development of a so-called SOM system in
17
      2013 or 2014. Do you recall that?
18
           Α.
                Yes.
19
20
                Was that threshold system I'll call it,
      was that developed because there was any view that
21
22
      the currently existing controls that you describe
23
      were viewed as inadequate in any way?
24
           Α.
                No. They were put together as an
25
      enhancement to the current process.
```

225 And that process, that threshold process 1 began in or about 2013? 2 3 Α. About per my recollection. And were enhancements made to that 4 Q. process over time? 5 Α. Yes. 6 7 Are you familiar with the CSOS system? Ο. Α. Yes. 8 Is that one of the enhancements? 9 Q. 10 CSOS was a system that just assisted in ordering CII through at the time it was the 11 12 wholesaler process, but it was -- it helped us --13 it was an enhancement for ordering CIIs, so from that perspective. 14 15 Q. Are you familiar with Supply Logics? 16 Α. Yes. Was that an enhancement to the threshold 17 Q. system? 18 Α. 19 Yes. 20 Q. What did Supply Logics allow you to do? Supply Logics had a couple components to 21 Α. 22 it that could allow us to audit and monitor. So 23 it would -- I can't remember. I'm trying to 24 visualize what this report looked like, but it would -- it basically would pull out -- allow us 25

226 to evaluate, investigate stores that were -- you 1 know, that stuck out in some fashion. 2 Q. At the pharmacy level you talked a 3 little bit about some of the controls at that 4 level. I just want to ask you generally. Were all 6 of the pharmacies staffed by licensed and trained 7 8 pharmacists? Α. Yes. 9 10 Were they staffed by trained technicians? 11 12 Α. Yes. 13 Were all of those individuals trained with respect to diversion? 14 15 There was a component of the training --I don't know specifically, but I know there were some discussions in the training around that. 17 Were there policies and procedures, 18 written policies and procedures in place at the 19 20 pharmacy level that assisted the pharmacists and 21 technicians with respect to filling appropriate 22 prescriptions? 23 Α. Yes. 24 Are you familiar with the DEA pharmacist manual? 25

```
227
 1
                MR. ROTTINGHAUS: Objection. Relevance.
                THE WITNESS: I may have seen it. I
 2
 3
      can't recall.
      BY MR. BARNES:
 4
                Do you recall if that was located at the
      pharmacies or accessible by the pharmacies?
 6
                Yeah. That should have been at each
 7
           Α.
      location, I believe.
 8
                Did Giant Eagle have controlled
 9
10
      substance dispensing guidelines?
                There were guidelines around controlled
11
12
      substances, yes.
13
               Did it include things like red flags,
      things to look out for before dispensing and
14
      filling a prescription?
15
           Α.
16
                Yes.
                MR. ROTTINGHAUS: Are you talking about
17
      at the pharmacy level or HBC level?
18
                MR. BARNES: Pharmacy level.
19
20
      BY MR. BARNES:
21
           Q. Are you familiar with the so-called
22
      OARRS system?
23
           Α.
                Yes.
24
           Q.
               What is that?
               It's an Ohio system to monitor
25
           Α.
```

228 1 prescription dispensing across the whole state. Is that something to your knowledge the 2 3 Giant Eagle pharmacists would access when filling a prescription as necessary? 4 Yes, as required. MR. ROTTINGHAUS: I didn't want to 6 7 interrupt. I'm interposing an objection on 8 relevance grounds. BY MR. BARNES: 9 10 Did the pharmacists or do the pharmacies 11 report their transactions to the DEA? I think you 12 already testified to that concerning the ARCOS 13 system. The ARCOS was one way. We also reported 14 dispensings through like the OARRS system and all 15 that. That was done at corporate level, but all 16 that information about the stores came from 17 corporate that was provided. 18 Did Giant Eagle have written fraud, 19 20 waste and abuse guidelines and procedures that 21 were at the pharmacies? 22 Α. Yes. 23 The record keeping at the pharmacies, 24 are you familiar with the term controlled substance boxes that maintain records? 25

229 Α. Yes. 1 Is that something when you were a PDL 2 you had to make sure every pharmacy complied with? 3 Α. The boxes either came out like right 4 when I was going onto my other position, the physical boxes that you're talking about. It 6 was -- I didn't physically do that as a PDL. I 7 think it came out just as I went on to my next 8 position. 9 10 But in your next position, did you learn what those were? 11 12 A. Yes. 13 What were they for generally? Just to kind of keep everything in one 14 place around controlled substances. 15 Would those include DEA forms, records 16 Ο. of invoices and transactions on controlled 17 substances? 18 DEA 222 forms, invoices, anything 19 20 regarding controlled substances. 21 Q. At the pharmacy level, were the controlled substances handled any differently than 22 23 any other drug? 24 A. Were they handled differently? Yes. Were they kept in a secure location? 25 0.

230 Any of the Schedule II were kept in a 1 locked location that only the pharmacist had 2 3 access to. And who could fill a controlled 4 substance II level prescription at the pharmacies? Could a tech do it, or was it a pharmacist 6 7 required? MR. ROTTINGHAUS: Objection. Relevance. 8 THE WITNESS: A pharmacist was required 9 10 to do that process. BY MR. BARNES: 11 12 And how were incoming orders of 13 controlled substances handled? Were there special procedures for those? 14 15 Yeah. We had formalized processes or procedures drawn up on how to receive an order, 16 and it even broke out controlled substances and 17 how to handle those orders specifically. 18 Were those orders checked against 19 20 invoices and immediately logged into inventory? 21 Α. Yes. Were there regular and then perpetual 22 23 inventories of all controlled substances? 24 A. Yes. There were Schedule IIIs through Vs were part of our perpetual. The CIIs were done 25

```
231
      in a manual fashion. So we're talking 2009 to
 1
      '14. It became part of the perpetual throughout
 2
 3
      that time period.
                You mentioned monthly narc audits. Was
 4
           Q.
      that for all controlled substances?
           Α.
                Yes.
 6
                And were there also annual controlled
 7
           Ο.
      substance inventories on top of the monthly narc
 8
      audits?
 9
10
                MR. ROTTINGHAUS: Objection. Leading.
                THE WITNESS: I'm sorry. Say that
11
12
      again.
      BY MR. BARNES:
13
                In addition to the monthly narc audits,
14
15
      were there regular annual inventories?
                MR. ROTTINGHAUS: Same objection.
16
                THE WITNESS: Yeah. We were required to
17
      do an every two-year inventory. We actually did
18
      ours on an annual basis.
19
2.0
      BY MR. BARNES:
                While controlled substance prescriptions
21
      were being filled, were there special accounting
22
23
      procedures employed to maintain control over every
24
     pill?
25
           Α.
               Yes.
```

232 MR. ROTTINGHAUS: Objection. Leading. 1 BY MR. BARNES: 2 Did the Ohio -- not only Ohio, but did 3 Ο. the state Boards of Pharmacy come into the 4 pharmacies on a random and unannounced basis and perform surprise inspections on a routine basis? 6 7 Α. Yes. Were there ever any problems that you 8 can recall involving controlled substances or 9 10 opioids? Α. Nothing specific to an inspection 11 12 regarding those products. 13 Q. And you were a PDL for a while? 14 Α. Yes. 15 And you had a region where you regularly Q. visited all your stores? 16 Α. 17 Yes. Were all of the pharmacies supervised by 18 a PDL in some way? 19 2.0 Α. Yes. And did they regularly visit the store 21 22 and conduct audits from time to time? 23 Α. Yes. 24 And did that include controlled substance procedures? 25

233 Α. Yes. 1 Did the PDL supervise training at the 2 3 pharmacies? Not directly supervise, but ensure that 4 all team members within that unit were trained. Did the PDLs work with law enforcement 6 and the Board of Pharmacy to deter diversion and 7 prosecute criminals? 8 MR. ROTTINGHAUS: Objection. Leading. 9 10 THE WITNESS: Yes. BY MR. BARNES: 11 12 Did the PDLs exercise red flag awareness 13 training in the pharmacies? 14 Α. Yes. 15 Would the PDLs have an opportunity to Q. observe while in these pharmacies suspicious activity, such as long lines out the door, things 17 of that nature? 18 Α. 19 Yes. 20 Q. And I think you said when you were a 21 PDL, you would assist from time to time with 22 threshold increases if the stores needed them; 23 right? 24 Α. When I was a PDL -- that was after I was a PDL when I was actually having the PDLs do the 25




































251 1 RE-EXAMINATION BY MR. BARNES: 2 Q. Just one follow-up question. After the 3 threshold daily report was instituted in or about 4 October of '13, did it reveal anything with respect to the adequacy of the controls that were 6 7 already in place? 8 Α. Based on --9 MR. ROTTINGHAUS: Let me make a quick 10 objection. Insufficient foundation. But go ahead. 11 12 THE WITNESS: Based on the limited 13 number of suspicious orders that were generated afterwards, I would say, no, it didn't really add 14 15 a whole lot to the process. But, again, we looked at it as an enhancement to what we had in place, 16 17 an extra stopgap. BY MR. BARNES: 18 Did it indicate one way or the other 19 20 whether the controls in place were adequate? I would evaluate it --21 Α. 22 MR. ROTTINGHAUS: Objection. Leading. 23 THE WITNESS: I would evaluate it to 24 show that we did have adequate controls in place from the beginning. 25

252 BY MR. BARNES: 1 Even after you instituted -- you 2 3 enhanced it with the threshold system? Α. Yes. MR. BARNES: Nothing further. RE-EXAMINATION (Continued) 6 7 BY MR. ROTTINGHAUS: Prior to 2014, was there ever a system 8 Q. in place where anyone at HBC was instructed when 9 10 they had an order that exceeded thresholds to ask any particular questions of the pharmacy to find 11 12 out and do a little more due diligence as to why 13 the order was exceeding threshold? 14 When you say threshold, HBC wasn't 15 looking at threshold information. They would look at unusual orders, being a large size, and that's 16 where they would ask the questions from. 17 And was there ever at any point in time 18 to your knowledge any documented instruction to 19 20 anyone at or on behalf of HBC as to what specific questions they should be asking of pharmacies when 21 22 they have an order that they thought was 23 extraordinarily large? 24 Their process was to notify myself or someone else at corporate to do the investigation 25



```
254
 1
      COMMONWEALTH OF PENNSYLVANIA )
      COUNTY OF ALLEGHENY
 2
                                   )
 3
                       CERTIFICATE
                I, Ann Medis, Registered Professional
 4
      Reporter, Certified Livenote Reporter and Notary
 5
      Public within and for the Commonwealth of
 6
      Pennsylvania, do hereby certify:
 7
                That GREGORY CARLSON, the witness whose
 8
      deposition is hereinbefore set forth, was duly
 9
10
      sworn by me and that such deposition is a true
      record of the testimony given by such witness.
11
12
                I further certify the inspection,
13
      reading and signing of said deposition were not
      waived by counsel for the respective parties and
14
      by the witness.
15
                I further certify that I am not related
16
      to any of the parties to this action by blood or
17
      marriage and that I am in no way interested in the
18
19
      outcome of this matter.
20
                IN WITNESS WHEREOF, I have hereunto set
      my hand this 11th day of January, 2019.
21
22
23
                                  Notary Public
24
25
```

		255
1	COMMONWEALTH OF PENNSYLVANIA) E R R A T A COUNTY OF ALLEGHENY) S H E E T	
2		
3	I, GREGORY CARLSON, have read the foregoing pages of my deposition given on January 8, 2019,	
4	and wish to make the following, if any, amendments, additions, deletions or corrections:	
5	ameriamentos, adaretens, derectons er corrections.	
6	Page Line Change and reason for change:	
7		
8		
9		
10		
11		
L2		
13		
L4		
15		
L6		
L7		
L8		
19	In all other respects, the transcript is true and correct.	
20		
21	GREGORY CARLSON	
22		
23	, day of, 2019.	
24 25	Notary Public	
- 0		